
With the participation of Seed Fonds III für die Region Aachen und Mönchengladbach GmbH & Co. KG and the US listed medical technology company Abiomed as lead investor, as well as coparion GmbH & Co. KG and other co-investors, the Aachen-based start-up Protembis GmbH successfully completed the financing round with around 10 million US dollars. The company intends to use this capital to bring its product to market maturity.
Protembis GmbH is developing a filter system designed to minimize the risk of stroke during catheter-guided heart valve transplants. With the innovative "ProtEmbo Cerebral Protection System" technology, or "ProtEmbo " for short, the company offers safety protection for the current method of transcatheter aortic valve implantation ("TAVI"), in which particles often enter the brain and can trigger a stroke.
The "ProtEmbo" filter device is inserted before the operation and removed again afterwards. While the permeable material of the "ProtEmbo" blocks access to the brain, it also allows blood cells to pass freely through the aorta without allowing embolic particles to pass through. In addition, the filter's heparin coating prevents the device from clogging during transplantation.
Both the initial safety and feasibility as well as the effectiveness of the ProtEmbo technology have already been proven in a clinical study in humans.